Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Warns of Deaths Tied To Gastric Balloons

Executive Summary

The agency doesn’t yet know the exact causes of the five deaths. This is the second safety alert on the obesity-treatment devices this year.

You may also be interested in...



EnteroMedics Inflates Neuromod-Obesity Offering With ReShape Balloon

The deal, worth $61m in cash and stock, will add ReShape's Dual Weight Loss Balloon to EnteroMedics' vBloc neurometabolic therapy and Gastric Vest System for the treatment of obesity.

Gastric Balloon-Makers Respond To US FDA Warning

Apollo Endosurgery and Reshape Medical are both defending their products’ safety in the wake of a US FDA letter warning of five deaths tied to the companies' intragastric balloon devices.

US FDA Warns Docs On Gastric Balloon Adverse Events

Gastric balloons from ReShape Medical and Apollo Endosurgery have been tied to pancreatitis and problems caused by over-inflation, the agency says.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT105305

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel